Illumina files 2026 Proxy - not exactly full of good news 🤷♂️
Annual bonus payout was 77% of target even though China was magically excluded 😳
Latest Coverage
Business
Gilead Expands Tempus AI Partnership for Real-World Data, AI Platform Access
The deal adds to Tempus's growing pharma data licensing business as the company simultaneously advances multiple FDA submissions for its sequencing-based CDx products.
Natera Secures 30% Royalty from Invitae, Drops NeoGenomics MRD Appeal
The dual resolution ends years of minimal residual disease patent litigation, delivering ongoing revenue from Invitae while clearing legal obstacles for NeoGenomics to expand its RaDaR assay.
Blackstone, TPG Close Hologic Acquisition, Name Baxter's Almeida CEO
The private equity firms completed their take-private of the women's health diagnostics company and installed a CEO known for cost restructuring, raising questions about Panther platform investment and competitive positioning.
Court Cuts Natera Award in Invitae MRD Patent Suit
The reduced damages follow a separate 30% royalty deal between the two companies and coincide with Natera's $52.5M bid for Invitae's reproductive health assets.
Clinical
23andMe Reports GLP-1 Pharmacogenomics Findings as Company Pursues Pharma Partnerships
Bankrupt consumer genetics firm identifies genetic variants linked to weight-loss drug response, positioning database for companion diagnostic deals.
Chinese CRISPR Therapy Reports 'Cures' in Five Blood Disease Patients
Results suggest Chinese gene editing developers can produce outcomes competitive with Vertex and CRISPR Therapeutics' approved therapy, though data remain limited.
GRAIL Partners with Junction to Expand Galleri Test Distribution
The collaboration adds a second access channel in two days, following Epic EHR integration, as GRAIL pursues volume growth without broad insurance coverage.
Waters Receives FDA 510(k) Clearance for Home-Collection HPV Test
The clearance marks the analytical instrument maker's entry into molecular diagnostics for cervical cancer screening.
Karolinska 10-Year Rare Disease Sequencing Study Published as WES Meta-Analysis Shows 37% Diagnostic Yield
New real-world evidence quantifies whole exome superiority over microarray in 55,752 pediatric cases, while Foundation Medicine liquid biopsy shows 2.8% detection rate for CNS mutations and Oxford Nanopore gains first EU diagnostic approval.
GRAIL Integrates Galleri Test Into Epic EHR Platform
Partnership embeds multi-cancer early detection test ordering into electronic health record system covering more than 305 million patient records nationwide.
Research
Trump Administration Drops NIH Overhead Cap Fight as $5B Budget Cut Looms
The reversal on indirect-cost reimbursements offers temporary relief to research institutions, but a proposed 2027 budget slash and foreign collaboration restrictions have already disrupted 25% of NIH-funded researchers.